Bilimsel çalışmalar

Doç. Dr. Sema Kaymaz Tahra

52 yayın. Her yayının yanında bilginin kaynağı yazar.

Profile dön
  1. Hematological Indices as Potential Biomarkers of Disease Activity in Ankylosing Spondylitis: LASSO-Based Multivariable Modelling

    Medicina, 2026

    DOI 10.3390/medicina62030497 PMID 41901578 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  2. Acute Motor Axonal Neuropathy Coexisting With Ankylosing Spondylitis: A Case‐Based Review

    Case Reports in Immunology, 2026

    DOI 10.1155/crii/5406702 PMID 42221920 1 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  3. Genetic susceptibility and validation of angiographic patterns in Takayasu arteritis

    Journal of Autoimmunity, 2025

    DOI 10.1016/j.jaut.2025.103496 PMID 41207179 3 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  4. ABS0104 Biological treatment may be an option as first steroid-sparing agent in a subgroup of young Takayasu Arteritis patients with prominent acute phase reactants and constitutional symptoms

    Annals of the Rheumatic Diseases, 2025

    DOI 10.1016/j.ard.2025.06.2016 Açık erişimli tam metinKaynak: OpenAlex

  5. POS0953 VASCULAR DAMAGE IS LESS PRESENT IN AN EARLY INCEPTION COHORT IN TAKAYASU'S ARTERITIS

    Annals of the Rheumatic Diseases, 2025

    DOI 10.1016/j.ard.2025.06.308 Açık erişimli tam metinKaynak: OpenAlex

  6. VASCULAR DAMAGE IS LESS PRESENT IN AN EARLY INCEPTION COHORT IN TAKAYASU’S ARTERITIS

    Kocaeli Üniversitesi - AVESİS, 2025

    Kaynak: OpenAlex

  7. Biological treatment may be an option as first steroid-sparing agent in a subgroup of young Takayasu Arteritis patients with prominent acute phase reactants and constitutional symptoms

    Kocaeli Üniversitesi - AVESİS, 2025

    Kaynak: OpenAlex

  8. Turkish Rheumatology Society (Turkish Takayasu Arteritis Study Group) recommendations for the diagnosis, follow-up and the treatment of Takayasu's arteritis

    Clinical and Experimental Rheumatology, 2025

    DOI 10.55563/clinexprheumatol/lptjx1 PMID 40658482 1 atıf (OpenAlex) Kaynak: OpenAlex

  9. Involvement of Iliofemoral Arteries in PET/CT Is Associated with Atherosclerotic Risk Factors in Takayasu’s Arteritis

    Journal of Clinical Medicine, 2025

    DOI 10.3390/jcm14238607 PMID 41375908 4 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  10. ABS0067 BIOLOGICAL THERAPIES MAY IMPROVE LONG-TERM OUTCOMES OF VASCULAR INTERVENTIONS IN PATIENTS WITH TAKAYASU ARTERITIS: A MULTICENTER RETROSPECTIVE STUDY

    Annals of the Rheumatic Diseases, 2025

    DOI 10.1016/j.ard.2025.06.2015 Açık erişimli tam metinKaynak: OpenAlex

  11. BIOLOGICAL THERAPIES MAY IMPROVE LONG-TERM OUTCOMES OF VASCULAR INTERVENTIONS IN PATIENTS WITH TAKAYASU ARTERITIS: A MULTICENTER RETROSPECTIVE STUDY.

    Kocaeli Üniversitesi - AVESİS, 2025

    Kaynak: OpenAlex

  12. Turkish Society for Rheumatology recommendations for the diagnosis, follow-up and management of giant cell arteritis

    Clinical and Experimental Rheumatology, 2025

    DOI 10.55563/clinexprheumatol/sghxo3 PMID 41930660 Açık erişimli tam metinKaynak: OpenAlex

  13. BIOLOGICAL TREATMENT MAY BE AN OPTION AS FIRST STEROID-SPARING AGENT IN A SUBGROUP OF YOUNG TAKAYASU ARTERITIS PATIENTS WITH PROMINENT ACUTE PHASE REACTANTS AND CONSTITUTIONAL SYMPTOMS

    Trakya University's Institutional Open Access System (Trakya University), 2025

    DOI 10.1136/annrheumdis-2025-eular.a1618 Açık erişimli tam metinKaynak: OpenAlex

  14. BIOLOGICAL THERAPIES MAY IMPROVE LONG-TERM OUTCOMES OF VASCULAR INTERVENTIONS IN PATIENTS WITH TAKAYASU ARTERITIS: A MULTICENTER RETROSPECTIVE STUDY

    Trakya University's Institutional Open Access System (Trakya University), 2025

    DOI 10.1136/annrheumdis-2025-eular.a1408 Kaynak: OpenAlex

  15. Comparison of Methotrexate and Azathioprine as the First Steroid-Sparing Immunosuppressive Agent in Patients with Takayasu's Arteritis

    Trakya University's Institutional Open Access System (Trakya University), 2025

    Açık erişimli tam metinKaynak: OpenAlex

  16. Comparison of methotrexate and azathioprine as the first-line steroid-sparing immunosuppressive agents in patients with Takayasu's arteritis

    Seminars in Arthritis and Rheumatism, 2024

    DOI 10.1016/j.semarthrit.2024.152446 PMID 38669786 15 atıf (OpenAlex) Kaynak: OpenAlex

  17. Frequency and the effects of spondyloarthritis-spectrum disorders on the clinical course and management of Takayasu arteritis: an observational retrospective study

    Clinical Rheumatology, 2024

    DOI 10.1007/s10067-024-06939-y PMID 38563865 8 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  18. Romatolojide Güncel Tedaviler

    Akademisyen Kitabevi eBooks, 2024

    DOI 10.37609/akya.2736 Açık erişimli tam metinKaynak: OpenAlex

  19. Biological Treatment May Be an Option as First Steroid-Sparing Agent in a Subgroup of Young Takayasu Arteritis Patients with Prominent Acute Phase Reactants and Constitutional Symptoms

    Kocaeli Üniversitesi - AVESİS, 2024

    Kaynak: OpenAlex

  20. Glucocorticoid toxicity index

    Acta Medica, 2024

    DOI 10.32552/2024.actamedica.1098 Açık erişimli tam metinKaynak: ORCID

  21. Takayasu arteritine eşlik eden spondiloartrit spektrumundaki hastalıkların sıklığı ve hastalık seyrine etkisi.

    Kocaeli Üniversitesi - AVESİS, 2023

    Kaynak: OpenAlex

  22. Hypogammaglobulinemia and severe infection risk in patients with autoimmune diseases during rituximab treatment

    Ulusal Romatoloji Dergisi, 2023

    DOI 10.4274/raed.galenos.2023.59144 Açık erişimli tam metinKaynak: OpenAlex

  23. Development of the Takayasu Arteritis Integrated Disease Activity Index

    Arthritis Care & Research, 2023

    DOI 10.1002/acr.25275 PMID 38059340 17 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  24. Metabolic syndrome is associated with increased cardiovascular risk and disease damage in patients with Takayasu arteritis

    International journal of rheumatic diseases, 2022

    DOI 10.1111/1756-185x.14335 PMID 35603731 6 atıf (Europe PMC) Açık erişimli tam metinKaynak: Europe PMC

  25. Pregnancy in Takayasu's arteritis has a high risk of hypertension-related fetomaternal complications: A retrospective study of a Turkish cohort

    International journal of rheumatic diseases, 2022

    DOI 10.1111/1756-185x.14247 PMID 34791826 6 atıf (Europe PMC) Kaynak: Europe PMC

  26. Assessment of Takayasu arteritis in routine practice with PETVAS, an 18F-FDG PET quantitative scoring tool

    Turkish Journal of Medical Sciences, 2022

    DOI 10.55730/1300-0144.5317 PMID 36161613 9 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  27. Disease activity and prognosis in Takayasu’s arteritis,Takayasu arteritinde aktivite değerlendirmesi ve prognoz

    Journal of Turkish Society For Rheumatology, 2022

    DOI 10.4274/raed.galenos.2022.97752 Açık erişimli tam metinKaynak: ORCID

  28. Biologic treatments in Takayasu's Arteritis: A comparative study of tumor necrosis factor inhibitors and tocilizumab

    Seminars in Arthritis and Rheumatism, 2021

    DOI 10.1016/j.semarthrit.2021.09.010 PMID 34706312 43 atıf (OpenAlex) Kaynak: OpenAlex

  29. The prevalence of non-vascular pulmonary manifestations in Takayasu’s Arteritis patients: A Retrospective multi-centred Turkish cohort study

    Scandinavian Journal of Rheumatology, 2021

    DOI 10.1080/03009742.2021.1972535 PMID 34643164 4 atıf (OpenAlex) Kaynak: OpenAlex

  30. Validation of Angiographic Patterns of Disease in a Turkish Cohort of Patients with Takayasu’s Arteritis.

    Kocaeli Üniversitesi - AVESİS, 2021

    Kaynak: OpenAlex

  31. Childhood-onset versus adult-onset Takayasu arteritis: A study of 141 patients from Turkey

    Seminars in Arthritis and Rheumatism, 2021

    DOI 10.1016/j.semarthrit.2020.10.013 PMID 33383295 23 atıf (Europe PMC) Kaynak: ORCID

  32. HADS-depression score is a mediator for illness perception and daily life impairment in Takayasu’s arteritis

    Clinical Rheumatology, 2021

    DOI 10.1007/s10067-021-05719-2 PMID 33839991 9 atıf (Europe PMC) Kaynak: ORCID

  33. Identification of susceptibility loci for Takayasu arteritis through a large multi-ancestral genome-wide association study

    American Journal of Human Genetics, 2021

    DOI 10.1016/j.ajhg.2020.11.014 PMID 33308445 47 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID

  34. The assessment of malnutrition and severity of gastrointestinal disease by using symptom-based questionnaires in systemic sclerosis: is it related to severe organ involvement or capillary rarefaction at microcirculation?

    Clin Exp Rheumatol, 2020

    PMID 32141434 7 atıf (OpenAlex) Açık erişimli tam metinKaynak: ORCID

  35. Assessment of damage in Takayasu‘s arteritis

    Seminars in Arthritis and Rheumatism, 2020

    DOI 10.1016/j.semarthrit.2020.04.003 PMID 32470706 19 atıf (Europe PMC) Kaynak: ORCID

  36. The assessment of malnutrition and severity of gastrointestinal disease using symptom-based questionnaires in systemic sclerosis: Is it related to severe organ involvement or capillary rarefaction at microcirculation?

    Clinical and Experimental Rheumatology, 2020

    Kaynak: ORCID

  37. AB0575 THE EFFECT OF METABOLIC SYNDROME ON CARDIOVASCULAR DISEASE AND CUMULATIVE ORGAN DAMAGE IN TAKAYASU'S ARTERITIS

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.4055 Açık erişimli tam metinKaynak: OpenAlex

  38. Pregnancy Outcome in Patients with Takayasu Arteritis: The Results of Turkish Takayasu Study Group.

    Kocaeli Üniversitesi - AVESİS, 2019

    Kaynak: OpenAlex

  39. CAN A ONE-HOUR QUANTITATIVE ASSESSMENT OF FDG-PET-CT (MODIFIED-PETVAS) BE USEFUL IN TAKAYASU'S ARTERITIS?

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.6843 Açık erişimli tam metinKaynak: ORCID

  40. 257. CAN A ONE-HOUR QUANTITATIVE ASSESSMENT OF FDG-PET-CT (MODIFIED-PETVAS) BE USEFUL IN TAKAYASU’S ARTERITIS?

    Rheumatology, 2019

    DOI 10.1093/rheumatology/kez062.031 Kaynak: OpenAlex

  41. AB0223 ASSESSMENT OF DISEASE ACTIVITY IN SYSTEMIC SCLEROSIS: THE COMPARISON BETWEEN REVISED EUSTAR AND ESCSG ACTIVITY INDEXES

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.6167 Açık erişimli tam metinKaynak: OpenAlex

  42. 256. ASSESSMENT OF DAMAGE IN TAKAYASU ARTERITIS PATIENTS WITH VASCULITIS DAMAGE INDEX (VDI) AND TAKAYASU ARTERITIS DAMAGE SCORE (TADS)

    Rheumatology, 2019

    DOI 10.1093/rheumatology/kez062.030 Açık erişimli tam metinKaynak: OpenAlex

  43. AB0596 ASSESMENT OF DAMAGE IN TAKAYASU ARTERITIS PATIENTS WITH VASCULITIS DAMAGE INDEX (VDI) AND TAKAYASU ARTERITIS DAMAGE SCORE (TADS)

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.6025 Açık erişimli tam metinKaynak: OpenAlex

  44. FRI0299 THE PREVALENCE OF NON-VASCULAR PULMONARY MANIFESTATIONS IN PATIENTS WITH TAKAYASU' ARTERITIS: A RETROSPECTIVE MULTI-CENTERED COHORT STUDY

    Annals of the Rheumatic Diseases, 2019

    DOI 10.1136/annrheumdis-2019-eular.3685 Açık erişimli tam metinKaynak: OpenAlex

  45. Takayasu arteritli hastalarda non-vasküler akciğer tutulum sıklığı: Çok merkezli retrospektif kohort sonuçları

    Kocaeli Üniversitesi - AVESİS, 2019

    Kaynak: OpenAlex

  46. Methodology of a new inflammatory arthritis registry: TReasure

    TURKISH JOURNAL OF MEDICAL SCIENCES, 2018

    DOI 10.3906/sag-1807-200 PMID 30119164 16 atıf (OpenAlex) Açık erişimli tam metinKaynak: OpenAlex

  47. Geç başlangıçlı spondilartrit hastalarında TNF inhibitörü tedavilerinin sürekliliği ve etkinliği: TReasure gerçek yaşam verileri

    Bursa Uludag University - AVESIS, 2018

    Kaynak: OpenAlex

  48. Takayasu arteritinde hastalık ile ilişkili gebelik prognozu.

    Kocaeli Üniversitesi - AVESİS, 2018

    Kaynak: OpenAlex

  49. Geç bafllang›çl› spondilartrit hastalar›nda TNF inhibitörütedavilerinin süreklili¤i ve etkinli¤i: TReasure gerçekyaflam verileri

    AYBU AVESIS, 2018

    Kaynak: OpenAlex

  50. Certolizumab pegol in the treatment of takayasu arteritis

    Rheumatology (United Kingdom), 2018

    DOI 10.1093/rheumatology/key197 PMID 30010945 18 atıf (Europe PMC) Açık erişimli tam metinKaynak: ORCID